Ticker Details
Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.
IPO Date:	March 3, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.18B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.40 | 2.81%
Avg Daily Range (30 D):	$0.55 | 2.39%
Avg Daily Range (90 D):	$0.46 | 2.17%

Institutional Daily Volume
Avg Daily Volume:	.63M
Avg Daily Volume (30 D):	1.26M
Avg Daily Volume (90 D):	1.15M

Trade Size
Avg Trade Size (Sh.):	85
Avg Trade Size (Sh.) (30 D):	66
Avg Trade Size (Sh.) (90 D):	65

Institutional Trades
Total Institutional Trades:	3,427
Avg Institutional Trade:	$2.29M
Avg Institutional Trade (30 D):	$2.41M
Avg Institutional Trade (90 D):	$2.37M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.99M
Avg Closing Trade (30 D):	$4.93M
Avg Closing Trade (90 D):	$4.19M
Avg Closing Volume:	167.53K

News

Mar 13, 2026 @ 1:09 PM Cancer Drug Maker With $172 Million Revenue and Mu... Source: Jonathan Ponciano

Jan 7, 2026 @ 12:00 PM Syndax and World Orphan Drug Alliance to Launch a ... Source: Na

Dec 1, 2025 @ 12:00 PM Syndax Announces Participation at the 8th Annual E... Source: Michael A. Metzger

Oct 24, 2025 @ 5:58 PM Syndax Announces FDA Approval of Revuforj® (rev... Source: Syndax Pharmaceuticals

Oct 10, 2025 @ 8:54 AM Menin Inhibitors Drug Market Report 2025: Price, S... Source: Researchandmarkets.Com

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.29	$-.78	$-3.29
Diluted EPS	$-3.29	$-.78	$-3.29
Revenue	$172.35M	$68.73M	$172.35M
Gross Profit
Net Income / Loss	$-285.42M	$-68.01M	$-285.42M
Operating Income / Loss	$-273.08M	$-62.55M	$-273.08M
Cost of Revenue
Net Cash Flow	$-19.27M	$18.01M	$-19.27M
PE Ratio